Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 10951 - 10975 of 11598 in total
ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)).
Investigational
Matched Description: … ORP-101 is under investigation in clinical trial NCT04129619 (A Comparison of the Effects of ORP-101 …
Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)).
Investigational
Matched Description: … Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and …
BN‐Brachyury vaccine is a novel prime‐boost therapeutic cancer immunotherapy. It is composed of the MVA-BN-brachyury-TRICOM vaccine and the fowlpox virus(FPV)‐Brachyury booster vaccine.
Investigational
Matched Description: … BN‐Brachyury vaccine is a novel prime‐boost therapeutic cancer immunotherapy. …
HMI-203 is an investigational gene therapy developed by Homology Medicines, Inc. It consists of a recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS).
Investigational
Matched Description: … It consists of a recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate …
AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.
Investigational
Developed by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a dual COX/LOX inhibitor and the first member of this new class of analgesic and anti-inflammatory drugs. It is currently under evaluation as a treatment for osteoarthritis (OA), the most common...
Investigational
Matched Description: … Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a ... It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis …
PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. It is developed for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease). In pre-clinical models, PYM50018 has been observed to protect against neuronal damage, increase neurite outgrowth, reverse oxidative damage and reverse neuronal apoptosis in...
Investigational
Matched Description: … PYM50018 is a patented, orally active, neuroprotective and neuroregenerative compound. ... When administered orally to a transgenic pre-clinical model of ALS, PYM50018 delays the loss of muscle …
99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging agent for the potential diagnosis of infection, including fever of unknown origin, osteomyelitis, wound infection, abdominal abscess, pneumonia, appendicitis and tuberculosis. INFECTON combines the widely used antibiotic, ciprofloxacin, with Technetium ((99m)Tc), the most commonly used radioisotope in...
Investigational
Matched Description: … 99mTc-Ciprofloxacin is a new formulation of ciprofloxacin (INFECTON), being investigated as a radioimaging …
Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to...
Investigational
Matched Description: … Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found ... The recruitment of macrophages to the arterial wall is believed to be a critical step in the development …
SYNB1020 is an engineered strain of Escherichia coli Nissle 1917 developed by Synlogic Inc. It was initially designed to convert ammonia to L-arginine and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016; however, the manufacturer discontinued further development of SYNB1020 to treat...
Investigational
Matched Description: … lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. ... however, the manufacturer discontinued further development of SYNB1020 to treat hyperammonemia due to a
3-Methyl-thiofentanyl is a fentanyl analog and an opioid analgesic that works by inducing central nervous system (CNS) depression.
Experimental
Illicit
Matched Description: … 3-Methyl-thiofentanyl is a [fentanyl] analog and an opioid analgesic that works by inducing central nervous …
MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.
Investigational
Matched Description: … MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. …
The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.
Investigational
Matched Description: … The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable …
N-sulfoglucosamine sulfohydrolase recombinant is under investigation for the treatment of Mucopolysaccharidosis III and Sanfilippo Syndrome Type A (MPS IIIA).
Investigational
Matched Description: … is under investigation for the treatment of Mucopolysaccharidosis III and Sanfilippo Syndrome Type A
Gambir is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Gambir is a plant/plant extract used in some OTC (over-the-counter) products. …
Pumice is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Pumice is a plant/plant extract used in some OTC (over-the-counter) products. …
LY-2881835 is under investigation in clinical trial NCT01358981 (A Study of LY2881835 in Healthy People and People With Diabetes).
Investigational
Matched Description: … LY-2881835 is under investigation in clinical trial NCT01358981 (A Study of LY2881835 in Healthy People …
LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer).
Investigational
Matched Description: … LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab …
Thymoquinone is a natural compound with widespread protective effects, including anti-oxidative, anti-inflammatory, immunomodulatory, anti-cancer, and anti-microbial.
Investigational
Matched Description: … Thymoquinone is a natural compound with widespread protective effects, including anti-oxidative, anti-inflammatory …
Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With Moderate-to-severe Atopic Dermatitis).
Investigational
Matched Description: … Torudokimab is under investigation in clinical trial NCT03831191 (A Study of LY3375880 in Adults With …
DSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain of SIRPα and 4-1BBL.
Investigational
Matched Description: … DSP107 is a bi-functional, trimeric, fusion protein composed of sequences from the extracellular domain …
SerpinPC is a mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for the treatment of hemophilia.
Investigational
Matched Description: … SerpinPC is a mutated alpha-1-antitrypsin (α1AT) and serine protease inhibitor being investigated for …
PNT001 is a humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated Thr231-Pro232 motif in tau.
Investigational
Matched Description: … PNT001 is a humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated …
TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1) messenger RNA.
Investigational
Matched Description: … TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1 …
An amino alcohol with a long unsaturated hydrocarbon chain. Sphingosine and its derivative sphinganine are the major bases of the sphingolipids in mammals. (Dorland, 28th ed)
Experimental
Matched Description: … An amino alcohol with a long unsaturated hydrocarbon chain. …
Displaying drugs 10951 - 10975 of 11598 in total